Gland Pharma share rises 2% in trade on Wednesday, June 4; here's why

Gland Pharma share price: Pharmaceutical company Gland Pharma shares increased as much as 1.58 per cent to hit an intraday high of 1,619 per share on Wednesday, June 4, 2025.
At 11:10 AM, Gland Pharma shares continued to trade near day's high, up 1.33 per cent at 1615 per share.
Why did Gland Pharma share price rise?
Gland Pharma shares rose after it secured United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Angiotensin II Acetate Injection 2.5 mg/mL.
'Gland Pharma Limited (Gland or Company), a generic injectable & ophthalmicfocused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Angiotensin II Acetate Injection 2.5 mg/mL,' Gland Pharma said, in a press release.
Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Giapreza of La Jolla Pharma LLC, the company revealed.
'Gland Pharma is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity,' the company claimed.
The product had US sales of approximately $58 million for the twelve months ending March 2025, according to IQVIA.
Gland Pharma Q4 results
Gland Pharma reported a 3 per cent year-on-year (YoY) decline in its consolidated net profit to ₹186.5 crore for the fourth quarter ended March 2025 (Q4FY25), compared to ₹192.4 crore in the same period last year.
Revenue from operations fell 7 per cent YoY to ₹1,424.9 crore from ₹1,537.5 crore. The company's Ebitda stood at ₹347.5 crore, marginally down from ₹358.7 crore a year ago.
However, the Ebitda margin improved to 24 per cent in Q4FY25, compared to 23 per cent in the corresponding quarter last year.
Research and development (R&D) expenses during the quarter were ₹50.3 crore, accounting for 4.9 per cent of revenue. For the full financial year FY25, R&D expenses stood at ₹192.2 crore, or 4.7 per cent of annual revenue.
Gland Pharma dividend
About Gland Pharma
Founded in 1978 in Hyderabad, Gland Pharma has evolved from a contract manufacturer of small-volume liquid parenterals to one of the largest injectable-focused pharmaceutical companies globally.
Operating predominantly under a B2B model, it has a presence in over 60 countries, including the US, Europe, Canada, Australia, and India.
The company's portfolio spans a wide range of sterile injectables such as vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, as well as oncology and ophthalmic products. Notably, it pioneered Heparin technology in India.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Mint

6 hours ago

• Mint

Four Indian pharma stocks that may be hit by US pharma tariff threat

Indian pharma stocks took a beating on Tuesday, 17 June, after US President Donald Trump said tariffs on pharmaceutical imports are coming 'very soon." His comments sent shockwaves across the market, dragging the Nifty Pharma index down by over 2% intraday. It was the worst-performing sector of the day. This isn't the first time Trump has hinted at such a move. He had dropped clues back in April, but this latest announcement has added urgency and concern. The Indian pharma industry, which relies heavily on exports to the US for generics and speciality drugs, is now facing concerns over potential revenue disruptions. Any disruption in trade or pricing could have a direct impact on revenues and margins. In this article, we take a look at five Indian pharmaceutical companies that could be the most affected by the proposed US tariffs. #1 Granules India Granules India has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies paracetamol, metformin, guaifenesin, and methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the US. The company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. As per the FY24 annual report, 66% of Granules India's total revenue came from North America. This dependence has only deepened in recent quarters with the US market contributing 79% of revenue in the March 2025 quarter, according to the latest investor presentation. Data Source: Earnings Presentation FY25 and Q4 FY25 Given this significant exposure, any tariff-related cost increases could affect both the company's topline and margins. On 17 June 2025, executive director Priyanka Chigurupati said that the company is currently in the final stages of completing remediation work at its Gagillapur facility. It expects this process to wrap up in the next few months, after which a USFDA re-inspection is anticipated. Once this hurdle is cleared, Granules is aiming to launch 11 pending products in the US market, which were temporarily held back during the compliance phase. Production had been scaled down to prioritise remediation, but the company is now preparing to ramp up volumes again as operations stabilise. It's also working on its first major oncology product launch in the US, expected around FY28. To support its future growth strategy, the company is prepping its Genome Valley facility to meet upcoming USFDA and European audits. #2 Gland Pharma Gland Pharma has become a leader in generic injectables. Its presence spans 60 countries, including the US, Europe, Canada, and Australia. The company's business model primarily involves business-to-business, which contributes 98% of its revenue. It provides contract development, dossier compilation, and technology transfer services. The balance comes from business to consumer. Geographically, the company has a strong presence in the US, which contributes 54% of its revenue. Its revenue in the region has grown from ₹2,585 crore in FY22 to ₹3,037 crore in FY24. This makes the company vulnerable to tariffs. Recently, Gland Pharma received approval from the US Food and Drug Administration (US FDA) for Angiotensin II Acetate Injection. Since the company is the first to submit for exclusivity, it qualifies for 180 days of exclusivity for the generic drug. #3 Aurobindo Pharma Aurobindo Pharma has built a strong presence across more than 150 countries, manufacturing generic formulations, APIs, and injectables. It's the largest generic drug company in the US and ranks among the top 10 generic players in eight European countries. That's where the concern comes in. According to its FY24 annual report, half (48%) of Aurobindo's revenue comes from the US. Data Source: Aurobindo Pharma Annual Report 2023-24 As per the company's investor presentation in March 2025, it holds the top spot in the US in terms of oral solids prescription volume, commanding a 10.5% market share in the September 2024 quarter. So, when talk of new US tariffs on pharma imports hits the headlines, Aurobindo's heavy exposure naturally makes the stock vulnerable to a fall. On 16 June 2025, the company announced the incorporation of a new wholly owned subsidiary, Cresedemo Pharma LLC, in the US. This move aims to further strengthen its US pharma business. While the new entity signals Aurobindo's long-term commitment to the US market, the proposed tariffs could present near-term headwinds for the company. Looking ahead, Aurobindo is placing a big bet on the future of biosimilars. With 14 promising products currently in the pipeline, the company is eyeing a massive US$ 50 bilion+ market opportunity. If things go as planned, this could open up an exciting new growth path and offer some much-needed cushion against any potential policy shocks like the proposed US tariffs. Also Read: India seeks financial details of pharmaceutical marketing practices, industry caught in a bind #4 Dr Reddy's Laboratories Dr Reddy's Lab is one of India's largest pharmaceutical firms in the country. The company manufactures a wide range of pharmaceuticals with expertise spanning several therapeutic areas. Through its step-down subsidiary Aurigene Pharmaceutical Services Ltd (APSL), it's making strong strides in the CDMO space. APSL acts as a comprehensive Contract Research, Development, and Manufacturing Organization (CRO/CDMO), offering end-to-end solutions to global pharmaceutical and speciality companies. It has cGMP manufacturing facilities in the UK, Mexico, USA, and India, enabling it to serve a global clientele. Despite this global footprint, a large chunk of Dr Reddy's revenue still comes from the US. Also, the latest investor presentation of Q4FY25, shows 42% of the total revenue from the US market. This heavy dependence on the US leaves the company exposed to the potential impact of new tariffs. In response to increasing tariff speculation, the company has indicated a desire to consider local manufacturing in the US, through acquisitions. This will not only help reduce the risk of import duties but will also deepen its foot in one of its most important markets. Meanwhile, Dr Reddy focuses on maintaining its growth. The company plans to launch 15-20 new products in the US every year. Also Read: Dr. Reddy's focused on securing supply chains amid US tariff uncertainty Conclusion While the possibility of imports has rattled the sector, it's important to take a balanced view before making investment decisions. There's no denying that companies with high revenue exposure to the US, like Aurobindo Pharma, Granules India, and Dr Reddy's could face near-term challenges if such tariffs are implemented. Margins may come under pressure and growth plans might require changes. However, the long-term fundamentals of India's pharmaceutical industry remain strong. The government is actively supporting the sector through key initiatives such as the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Promotion of Bulk Drug Parks, Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to make quality medicines accessible at affordable prices. Moreover, according to a recent EY-FICCI report, the Indian pharmaceutical market is poised to reach a value of around $130 billion by 2030, signalling strong growth potential. It's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance. Happy Investing. Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. This article is syndicated from

Indian Express

16 hours ago

• Indian Express

As US FDA approves HIV prevention drug Lenacapavir, expert says ‘India needs to take lead for its equitable, timely distribution

The United States Food and Drug Administration (FDA) on Wednesday approved Lenacapavir (LEN), the most promising HIV prevention medicine to be made so far, and according to Dr I S Gilada, president emeritus, AIDS Society of India, the real breakthrough would be when LEN becomes accessible, affordable and available to everyone in India and across the world. Lenacapavir is an antiretroviral medicine that is used for HIV prevention as a pre-exposure prophylaxis or PrEP. PrEP is a medication that can reduce the risk of HIV infection for individuals who are HIV-negative but are at risk of contracting the virus. The results of two key studies have shown that it helps prevent 99.9 per cent of all HIV transmission. 'LEN is an injectable PrEP that is to be taken twice yearly,' said Dr Glory Alexander, president of AIDS Society of India (ASI) and founder director of ASHA Foundation, Bengaluru. PrEP was first approved by the US FDA in 2012, but the Indian government's National AIDS Control Organisation is yet to roll it out. 'If we invest in HIV prevention, we not only protect people's health but also save expenses in providing lifelong HIV care, including lifelong antiretroviral therapy (ART). HIV prevention must remain at the centre-stage of our national AIDS response,' said Dr Gilada. 'Indian regulators should work with Indian generic manufacturing companies to ensure that 'made in India' generic LEN versions when available, are first rolled out in India,' Dr Gilada told The Indian Express. 'The scientific breakthrough translates into public health impact in terms of stopping the spread of HIV infection. The major impediment is the cost: LEN as PrEP to be sold as Yeztugo by Gilead is priced at US$ 28,218 per person per year. However, Gilead's wisdom by giving voluntary licenses to four Indian generic companies, gives hope that the medicine may cost less than US$ 100 – that is 0.3 per cent of the innovator's cost,' Dr Gilada explained. 'India needs to lead from the front for LEN's equitable and timely distribution at the required scale to prevent HIV transmission and help end AIDS,' said Dr Gilada, adding that only India can deliver LEN to all those in need worldwide, in terms of quality, quantity and speed. Though India meets 92 per cent of the global requirement for ART and the global community (WHO, UNAIDS, Global Fund, World Bank, etc) widely uses Indian generic pharma for their strategies like Treatment as Prevention (TasP), Test and Treat, Post-exposure Prophylaxis (PEP), PreP, etc, it is unfortunate that they are shy to acknowledge this, he said. Gilead had faced a lot of backlash from health advocates and communities last year over the astronomical pricing for LEN, pegged at over US$ 40,000 per person per year, which has now been slashed by 30 per cent. Earlier, Gilead's Hepatitis C treatment, which cost $84,000 in the US for a three-month course, was made available in India for less than $300. So the firm knew what was to be done this time, and granted voluntary licensing to six generic manufacturers, including four Indian: Dr Reddy's Laboratories, Emcure, Hetero Healthcare, and Viatris. 'All international antiretroviral therapy and prevention guidelines are conceptualised and implemented on the strength of India. Only India can meet the global demand for LEN at such low cost, just as it did for ART, at 0.3 per cent of the innovator's cost,' Dr Gilada said. Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition. ... Read More

Business Standard

a day ago

• Business Standard

Natco Pharma receives seven observations from USFDA Following Inspection at Kothur Facility

Natco Pharma announced that its pharmaceutical manufacturing facility in Kothur, Hyderabad, has received seven observations from the United States Food and Drug Administration (USFDA) following a recent inspection. In a regulatory filing, the company stated that the USFDA conducted the inspection from 9 June to 19 June 2025. At the conclusion of inspection, the USFDA has issued a Form 483 with seven observations. Natco Pharma expressed confidence in addressing the observations within the stipulated timeline and reaffirmed its commitment to current Good Manufacturing Practices (cGMP) and the consistent supply of high-quality pharmaceutical products to global markets. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The companys consolidated net profit increased 5.3% to Rs 406.60 crore on a 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24. The counter shed 0.98% to Rs 872.75 on the BSE.